Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for colorectal cancer (CRC) in patients with type 2 diabetes, with and without overweight or obesity, according ...
Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular profile. This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers ...
Cardiff Oncology completed patient enrollment in the Phase 2 CRDF-004 trial for RAS-mutated mCRC, with data expected in 2025. Cardiff Oncology, Inc. announced the completion of patient enrollment in ...
Disparities in prophylactic tetracycline use among patients with metastatic colorectal cancer undergoing treatment with EGFR inhibitors. Impact of unplanned readmission to the same facility within 30 ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II ...
The firm is testing the activity of AN9025 in patients with various solid tumors harboring KRAS, NRAS, or HRAS mutations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results